DataMeds AI Acquires Cancer Diagnostics Assets from Todos Medical
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
DataMeds AI agreed to acquire certain assets from the estate of Todos Medical Ltd. These assets include Cancer AI Total Biochemical Infrared Analysis blood tests for breast and colorectal cancer. The platform utilizes Fourier-transform infrared spectroscopy biochemical analysis of blood plasma. The acquired tests hold CE Marks in Europe and have issued patents in the U.S. and Europe.
From timesargus.com
Why it matters
The acquisition provides DataMeds AI with proprietary diagnostic technology, including US patents offering exclusivity until at least 2034. The company plans to use the platform, which will be transferred to Helomics, to revalidate data before seeking FDA approval.
From timesargus.com
Who's involved
- Todos MedicalThe company whose estate provided the cancer diagnostics assets
- GRAILA competitor in the American biotechnology and pharmaceutical sector
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- GRAILSpeculative
GRAIL might face increased competition in the cancer diagnostic market, potentially affecting sales.
- European Medicines AgencySpeculative
The European Medicines Agency may increase regulatory oversight of the diagnostic platform in Europe, affecting compliance costs.
- NasdaqSpeculative
Nasdaq could see increased market confidence in DataMeds AI due to the acquisition of patented assets, potentially affecting investment valuation.
Keep exploring
The entities involved
Related events
- An AI-designed drug is currently in trials, prompting a focus on global legal and ethical standards.
- The FDA is a U.S. government agency, a basic descriptive fact about the regulator.
- FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.